Literature DB >> 18355236

Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data.

A Ringborg1, M Martinell, J Stålhammar, D D Yin, P Lindgren.   

Abstract

AIMS: To examine medical resource use of Swedish patients with type 2 diabetes during 2000-2004 and to estimate annual costs of care.
METHODS: Retrospective population-based cohort study of patients with type 2 diabetes identified in computerised medical records at 26 primary care centres in Uppsala county, Sweden. Annual quantities of medical resources were determined for prevalent cases during 2000-2004 using register data from outpatient primary care, outpatient hospital care, the National Inpatient Register and a national register for treatment of uraemia. Average costs of care of patients with type 2 diabetes were estimated based on year 2004 resource quantities of 8230 prevalent study cases.
RESULTS: Annual quantities of medical resource use were stable in outpatient primary care and outpatient hospital care, with patients making an average of two General Practitioner visits and 3.5 outpatient hospital visits each year. Higher rates of hospitalisation [12% in 2000 (n = 6711) compared with 16% in 2004 (n = 8230)] led to an increase in the mean (SD) number of inpatient days from 2.3 (11.8) to 2.7 (11.9) (p = 0.040) between 2000 and 2004. Mean (SD) total costs of care in 2004 were EUR 3602 (EUR 9537). Inpatient care was the major contributor to costs, accounting for 57% of total costs while drug costs accounted for an average 7%.
CONCLUSIONS: Swedish type 2 diabetic patients in this large sample from Uppsala county required steady annual amounts of outpatient care and increasing amounts of inpatient care during 2000-2004. The associated costs in 2004 were substantial, with inpatient care identified as the most important component.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18355236     DOI: 10.1111/j.1742-1241.2008.01716.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  18 in total

1.  The Effect of Canola Oil on Body Weight and Composition: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.

Authors:  Hamidreza Raeisi-Dehkordi; Mojgan Amiri; Karin H Humphries; Amin Salehi-Abargouei
Journal:  Adv Nutr       Date:  2019-05-01       Impact factor: 8.701

Review 2.  The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.

Authors:  Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Layal Chaker; Sven J van der Lee; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Abby Falla; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-01-18       Impact factor: 8.082

3.  Living with diabetes: rationale, study design and baseline characteristics for an Australian prospective cohort study.

Authors:  Maria Donald; Jo Dower; Robert Ware; Bryan Mukandi; Sanjoti Parekh; Christopher Bain
Journal:  BMC Public Health       Date:  2012-01-05       Impact factor: 3.295

4.  Risk of cancer following hospitalization for type 2 diabetes.

Authors:  Kari Hemminki; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  Oncologist       Date:  2010-05-17

5.  Automated data extraction--a feasible way to construct patient registers of primary care utilization.

Authors:  Mats Martinell; Jan Stålhammar; Johan Hallqvist
Journal:  Ups J Med Sci       Date:  2012-03       Impact factor: 2.384

Review 6.  The Economic Costs of Type 2 Diabetes: A Global Systematic Review.

Authors:  Till Seuring; Olga Archangelidi; Marc Suhrcke
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

7.  Subsequent Type 2 Diabetes in Patients with Autoimmune Disease.

Authors:  Kari Hemminki; Xiangdong Liu; Asta Försti; Jan Sundquist; Kristina Sundquist; Jianguang Ji
Journal:  Sci Rep       Date:  2015-09-09       Impact factor: 4.379

8.  Risk equations for the development of worsened glucose status and type 2 diabetes mellitus in a Swedish intervention program.

Authors:  Anne Neumann; Margareta Norberg; Olaf Schoffer; Fredrik Norström; Ingegerd Johansson; Stefanie J Klug; Lars Lindholm
Journal:  BMC Public Health       Date:  2013-10-26       Impact factor: 3.295

9.  Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.

Authors:  S E Kjeldsen; J Stålhammar; P Hasvold; J Bodegard; U Olsson; D Russell
Journal:  J Hum Hypertens       Date:  2009-11-05       Impact factor: 3.012

10.  Familial risks for type 2 diabetes in Sweden.

Authors:  Kari Hemminki; Xinjun Li; Kristina Sundquist; Jan Sundquist
Journal:  Diabetes Care       Date:  2009-11-10       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.